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mortality between facilities, and could 
also facilitate comparisons for other out-
comes, including hospitalizations and 
costs. In the current environment of 
exceedingly high costs of ESRD care and 
nationwide eff orts to control costs and 
maximize quality and outcomes in 
patients with chronic diseases, there is 
likely to be increasing interest in compar-
ing facilities and even individual physi-
cians on the basis of costs, quality, and 
outcomes of maintenance dialysis treat-
ment. Accurate accounting for patient 
comorbidity — using tools such as the 
index developed by Liu  et al. 7 — will be an 
essential component of these eff orts. 
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 Th e list of therapeutic gases continues to 
grow. Previous studies have reported on 
the benefi cial eff ects of gases such as nitric 
oxide (NO), carbon monoxide (CO), and, 
more recently, hydrogen sulfi de (H 2 S) in 
animal models of many diseases. 1 – 3 
Inhaled NO is already in clinical use for 
the treatment of hypoxic respiratory 
failure and pulmonary hypertension, par-
ticularly in neonates, and additional uses 
of NO are being investigated in other set-
tings of lung and cardiac diseases. 4 Con-
vincing preclinical data have prompted 
the initiation of clinical trials involving 
the use of inhaled CO for delayed graft  
function in kidney transplant recipients 
and H 2 S (using sodium sulfi de) in patients 
undergoing coronary artery bypass 
 surgery and in patients with impaired 
renal function ( http://www.clinicaltrials.
gov ). Cardinal and colleagues 5 (this issue) 
now describe the use of yet another prom-
ising gaseous molecule, hydrogen (H 2 ), as 
a treatment for chronic allograft  nephro-
pathy (CAN) in a rat model of kidney 
transplantation. Th ey nicely demonstrate 
that rat kidney allograft recipients fed 
water containing dissolved H 2 exhibited 
better graft  survival, reduced incidence 
of CAN, lower levels of reactive oxygen 
species (ROS), and reduced activation of 
proinfl ammatory secretory and signaling 
pathways. CAN (also called interstitial 
fi brosis and tubular atrophy of unknown 
etiology (IF / TA)) remains one of the most 
vexing clinical entities for the renal trans-
plant physician because it is remarkably 
recalcitrant to current treatment moda-
lities and is a major cause of long-term 
graft loss. 6 Therefore, potential new 
approaches to the treatment of CAN such 
as the one described by Cardinal and 
colleagues 5 are of great interest. 
 Hydrogen is the first element in 
the periodic table and constitutes at 
least 90 % of the observable universe. 
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 Hydrogen: another gas 
with therapeutic potential 
 James F.  George 1 , 2 and  Anupam  Agarwal 2 , 3   
 Cardinal and colleagues describe the use of molecular hydrogen, the 
most abundant molecule in the universe, as a treatment for chronic 
allograft nephropathy (CAN) in a rat model of kidney transplantation. 
They demonstrate that the addition of hydrogen to the drinking water 
results in a decrease in the severity of CAN and increased graft survival, 
and they provide evidence that the mechanism of action could be due 
to a reduction in reactive oxygen species. 
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Robert Boyle (1671) was the first to 
 produce hydrogen when he dissolved iron 
in diluted hydrochloric acid. Th is obser-
vation occurred long before it was actually 
discovered as a distinct gas in 1766 by 
Henry Cavendish, who originally called it 
 ‘ inflammable air ’ ; it was later named 
hydrogen (Greek  hydro ,  ‘ water, ’ and  genes , 
 ‘ forming ’ ) by Lavoisier, the father of mod-
ern chemistry. On earth, free hydrogen is 
comparatively rare. Th e majority of hydro-
gen found on earth is in water and organic 
compounds. It is highly reactive in the 
presence of  specifi c catalysts and / or heat. 
One of the more spectacular examples of 
its reactivity was shown in 1937 when the 
zeppelin  Hindenburg , using hydrogen for 
lift , ignited and was destroyed in less than 
a minute in the ensuing confl agration. 
Th erefore, the use of hydrogen as a thera-
peutic agent is not intuitively obvious. 
However, recent data have shown that 
hydrogen can behave as an antioxidant in 
biological systems because of its ability to 
reduce ROS. 7 ROS or free radicals, such 
as the superoxide anion (O 2   −   ), are gener-
ated through the leak of electrons to 
molecular oxygen in the mitochondria 
during the production of adenosine tri-
phosphate by oxidative phosphorylation 
( Figure 1 ). In the normal state, mitochon-
dria generate 2 – 3  nmol of superoxide 
anion per minute per milligram of pro-
tein, 8 resulting in the generation of the 
superoxide radical, hydrogen peroxide, 
and the highly toxic hydroxyl radical. 
Th ese ROS can be safely reduced to water 
by superoxide dismutase, catalase, and 
glutathione peroxidase ( Figure 1 ). During 
ischemia – reperfusion injury, which inev-
itably occurs during organ transplanta-
tion, the balance between the generation 
of ROS and the mechanisms to detoxify 
them can be upset,  resulting in 
the accumulation of ROS in the tissues, 
where they quickly react with lipids, pro-
teins, and nucleic acids, causing dis-
ordered cellular functions. 
 The paper by Cardinal and col-
leagues 5 is based on the premise that 
oxidat ive  stress ,  result ing f rom 
ischemia – reperfusion, is a common 
pathway of injury in the setting of 
transplantation and is therefore a sig-
nificant contributor to the deve lopment 
of CAN. These findings are an exten-
sion of the elegant work of Ohsawa and 
colleagues, who were the first to dem-
onstrate that inhalation of hydrogen gas 
was an effective antioxidant strategy in 
cultured neuronal cells and in a model 
of ischemia – reperfusion in the brain 
 in vivo . 7 These authors also showed that 
hydrogen gas was capable of rapidly dif-
fusing through membrane compart-
ments, gaining ready access to the cytosol, 
mitochondria, and nucleus and reducing 
hydroxyl radicals (·OH; the strongest of 
oxidant species in living cells) but did not 
appear to compromise essential homeo-
static mechanisms dependent on ROS. 7 
Cardinal and colleagues 5 show that the 
administration of water containing dis-
solved hydrogen results in (1) a sustained 
increase in the levels of hydrogen in the 
kidney and serum, without any accumula-
tion over time; (2) improved kidney allo-
graft  function over a 60-day follow-up 
period; (3) a decrease in several markers 
of infl ammation, including graft -infi ltrat-
ing cells, proinfl ammatory cytokines, and 
mitogen-activated protein kinase activa-
tion; and (4) decreased levels of lipid per-
oxides and peroxynitrite in the tissues. 
 A variety of other gases, such as NO, 
CO, and H 2 S, are considered poisonous in 
large amounts but, in smaller concentra-
tions, have antioxidant properties or are 
involved in physiological functions. Given 
previous data, the interpretation that the 
benefi cial eff ects of H 2 in a kidney trans-
plant model are a result of antioxidant 
properties of the element is reasonable 
and likely. However, this may not be the 
sole explanation, and other as-yet unde-
fi ned mechanisms may be involved. Th e 
presence of basal levels of H 2 indicates one 
or more endogenous sources, suggesting 
that it plays a physiological role. Precedent 
for this possibility can be easily found in 
other gas-generating systems. CO, which 
is endogenously generated during the 
degradation of heme by the heme oxyge-
nase enzyme system, 9 was previously 
thought of exclusively as a toxic gas. It is 
now understood that CO, which also has 
benefi cial eff ects in infl ammation and oxi-
dative stress, plays a physiological role and 
participates in several signaling pathways 
known to modulate inflammation. 2 
In fact, several clinical trials using inhaled 
CO are ongoing, including one in kidney 
transplant recipients. NO has attracted the 
most attention because of its involvement 
in cardiovascular biology, blood pressure 
regulation, and kidney and vascular func-
tion. NO is generated from arginine by 
nitric oxide synthases and has a number 
of molecular targets, including guanylate 
cyclase (which CO also targets) and phos-
phodiesterases. 1 Therefore, given the 
increasing number of systems in which H 2 
is being shown to mediate beneficial 
eff ects, and likely, in the future, deleteri-
ous ones as well, it is probable that involve-
ment of H 2 in signaling pathways or other 
physiological functions will be found. Th e 
molecular gases, H 2 , NO, and H 2 S are 
much simpler in structure than many of 
the drugs in use today.  Our knowledge of 
them will continue to expand, providing 
an exciting potential for an entirely new 
class of drugs in the treatment of kidney 
diseases and end-stage organ failure. 
 Figure 1  |  A schematic of reactive oxygen species generation in the mitochondria.  Oxygen 
radicals are colored red. The potential sites for the neutralizing antioxidant effects of 
molecular hydrogen are  shown. SOD-super oxide dismutase. 
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